Last reviewed · How we verify
Any prophylaxis for GVHD
At a glance
| Generic name | Any prophylaxis for GVHD |
|---|---|
| Also known as | Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any in vitro or in vivo. |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
- Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant (PHASE2)
- Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT (PHASE2)
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (PHASE1)
- Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. (PHASE1, PHASE2)
- Methods of T Cell Depletion Trial (MoTD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: